Bellevue Group AG Trims Holdings in Stryker Co. (NYSE:SYK)

Bellevue Group AG reduced its holdings in shares of Stryker Co. (NYSE:SYK) by 3.5% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 449,340 shares of the medical technology company’s stock after selling 16,384 shares during the period. Stryker makes up 2.5% of Bellevue Group AG’s investment portfolio, making the stock its 12th largest holding. Bellevue Group AG owned about 0.12% of Stryker worth $160,805,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Burkett Financial Services LLC acquired a new stake in shares of Stryker in the 4th quarter worth $25,000. Farmers & Merchants Trust Co of Chambersburg PA boosted its holdings in Stryker by 203.3% in the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 61 shares in the last quarter. Rogco LP acquired a new position in Stryker during the 4th quarter worth approximately $30,000. DSM Capital Partners LLC acquired a new stake in shares of Stryker in the 4th quarter valued at approximately $34,000. Finally, HBC Financial Services PLLC purchased a new stake in shares of Stryker in the fourth quarter valued at approximately $37,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Trading Up 1.3 %

NYSE SYK traded up $4.23 during mid-day trading on Friday, reaching $331.67. 1,679,993 shares of the stock were exchanged, compared to its average volume of 1,084,425. Stryker Co. has a 1-year low of $249.98 and a 1-year high of $361.41. The stock has a market capitalization of $126.35 billion, a PE ratio of 37.86, a PEG ratio of 2.61 and a beta of 0.89. The business’s fifty day simple moving average is $338.99 and its 200 day simple moving average is $339.32. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.99 and a current ratio of 1.71.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share for the quarter, topping the consensus estimate of $2.36 by $0.14. Stryker had a return on equity of 23.05% and a net margin of 16.03%. The firm had revenue of $5.24 billion for the quarter, compared to the consensus estimate of $5.10 billion. During the same period in the prior year, the business posted $2.14 earnings per share. The firm’s revenue for the quarter was up 9.7% compared to the same quarter last year. On average, research analysts anticipate that Stryker Co. will post 11.95 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th will be paid a dividend of $0.80 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.20 annualized dividend and a dividend yield of 0.96%. Stryker’s dividend payout ratio is presently 36.53%.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. UBS Group raised their target price on Stryker from $339.00 to $351.00 and gave the company a “neutral” rating in a report on Wednesday, May 1st. Royal Bank of Canada increased their target price on shares of Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a report on Monday, April 15th. StockNews.com upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research report on Thursday, July 11th. Roth Mkm raised their price objective on Stryker from $348.00 to $405.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. Finally, Needham & Company LLC upgraded Stryker from a “hold” rating to a “buy” rating and set a $392.00 target price on the stock in a research report on Wednesday, May 22nd. Four equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $372.05.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.